Patents by Inventor Kenneth Gordon Carson

Kenneth Gordon Carson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120302562
    Abstract: Compounds that may be used to inhibit Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting bone.
    Type: Application
    Filed: May 23, 2012
    Publication date: November 29, 2012
    Inventors: Joseph BARBOSA, Kenneth Gordon CARSON, Michael Walter GARDYAN, Jason Patrick HEALY, Qiang HAN, Ross MABON, Praveen PABBA, James TARVER, JR., Kristen M. TERRANOVA, Ashok TUNOORI, Xiaolian XU
  • Publication number: 20120225857
    Abstract: Compounds for the inhibition of mammalian Ste20-like kinase 1 (MST1) are disclosed, along with compositions comprising them and methods of their use in the treatment, management or prevention of an inflammatory or autoimmune diseases or disorders.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 6, 2012
    Inventors: David John Augeri, Jeffrey Thomas Bagdanoff, Simon David Peter Baugh, Marianne Carlsen, Kenneth Gordon Carson, John Anthony Gilleran, Wei He, Tamas Oravecz, Konstantin Salojin, Leonard Sung
  • Publication number: 20120065200
    Abstract: Compounds are disclosed for the treatment, management and prevention of diseases and disorders affecting the bone. Particular compounds are potent inhibitors of Notum Pectinacetylesterase, and are of the formula: wherein E, G, Y, Z, R1, R2, and R3 are defined herein.
    Type: Application
    Filed: September 13, 2011
    Publication date: March 15, 2012
    Inventors: Joseph BARBOSA, Kenneth Gordon CARSON, Michael Walter GARDYAN, Wei HE, Victoria LOMBARDO, Praveen PABBA, James TARVER, JR.
  • Patent number: 6458806
    Abstract: Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection where V═O,S, NH or a bond; Ar can be unsubstituted or substituted benzimidazole, phenyl, biphenyl, pyridyl, naphthyl, quinoline or isoquinoline. The other meanings for the terms are recited in the specification below.
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: October 1, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Richard John Booth, Kenneth Gordon Carson, David Thomas Connor, Roberta Ellen Glynn, Bruce David Roth, Charles F. Schwender, Bharat Kalidas Trivedi, Paul Charles Unangst
  • Publication number: 20020028833
    Abstract: Aryl alkenamides derivatives of Formula I or a pharmaceutically acceptable salt thereof are novel MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection 1
    Type: Application
    Filed: August 12, 1997
    Publication date: March 7, 2002
    Inventors: RICHARD JOHN BOOTH, KENNETH GORDON CARSON, DAVID THOMAS CONNOR, ROBERTA ELLEN GLYNN, BRUCE DAVID ROTH, CHARLES F. SCHWENDER, BHARAT KALIDAS TRIVEDI, PAUL CHARLES UNANGST